Skip to main content

Table 2 Patient characteristics in the NORDIC-VII study

From: Let-7 miRNA-binding site polymorphism in the KRAS 3UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/− cetuximab

  LCS6 wild-type (N=451) LCS6 variant (N=84)
Arm A B C A B C
N 154 148 149 26 33 25
% 86 82 86 14 18 14
Age, years
Median 60.4 60.8 63.7 63.8 60.6 62.3
Min 29.9 24.1 33.1 37.1 38.0 36.3
Max 74.8 74.4 74.9 74.7 73.7 74.0
Sex (%)
Male 56 63 60 46 70 76
Female 44 37 40 54 30 24
Location primary tumor (%)
Colon 55 53 66 65 61 52
Rectum 45 47 34 35 39 48